T2 Biosystems Inc. (NASDAQ:TTOO) went down by -10.95% from its latest closing price compared to the recent 1-year high of $3.79. The company’s stock price has collected -23.87% of loss in the last five trading sessions. Press Release reported on 02/08/21 that T2 Biosystems to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference
Is It Worth Investing in T2 Biosystems Inc. (NASDAQ :TTOO) Right Now?
Plus, the 36-month beta value for TTOO is at 0.63. Opinions of the stock are interesting as 4 analysts out of 5 who provided ratings for T2 Biosystems Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $3.18, which is $0.66 above the current price. TTOO currently public float of 140.78M and currently shorts hold a 6.48% ratio of that float. Today, the average trading volume of TTOO was 11.80M shares.
TTOO’s Market Performance
TTOO stocks went down by -23.87% for the week, with a monthly jump of 34.04% and a quarterly performance of 123.01%, while its annual performance rate touched 180.00%. The volatility ratio for the week stands at 9.23% while the volatility levels for the past 30 days are set at 13.95% for T2 Biosystems Inc.. The simple moving average for the period of the last 20 days is -7.57% for TTOO stocks with a simple moving average of 74.01% for the last 200 days.
Analysts’ Opinion of TTOO
Many brokerage firms have already submitted their reports for TTOO stocks, with Alliance Global Partners repeating the rating for TTOO by listing it as a “Neutral.” The predicted price for TTOO in the upcoming period, according to Alliance Global Partners is $2.40 based on the research report published on January 27th of the current year 2021.
BTIG Research, on the other hand, stated in their research note that they expect to see TTOO reach a price target of $2.50. The rating they have provided for TTOO stocks is “Buy” according to the report published on October 08th, 2020.
TTOO Trading at 32.09% from the 50-Day Moving Average
After a stumble in the market that brought TTOO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.51% of loss for the given period.
Volatility was left at 13.95%, however, over the last 30 days, the volatility rate increased by 9.23%, as shares surge +34.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +117.24% upper at present.
During the last 5 trading sessions, TTOO fell by -23.87%, which changed the moving average for the period of 200-days by +380.00% in comparison to the 20-day moving average, which settled at $2.76. In addition, T2 Biosystems Inc. saw 103.23% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at TTOO starting from Barclay Alec, who sale 5,808 shares at the price of $0.82 back on Feb 24. After this action, Barclay Alec now owns 46,294 shares of T2 Biosystems Inc., valued at $4,763 using the latest closing price.
Gibbs Michael Terrence, the General Counsel of T2 Biosystems Inc., sale 5,808 shares at $0.82 during a trade that took place back on Feb 24, which means that Gibbs Michael Terrence is holding 60,779 shares at $4,763 based on the most recent closing price.
Stock Fundamentals for TTOO
Current profitability levels for the company are sitting at:
- -624.57 for the present operating margin
- -101.12 for the gross margin
The net margin for T2 Biosystems Inc. stands at -707.93. Equity return is now at value 714.40, with -96.50 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 10.67, with the company’s debt to enterprise value settled at 0.53. The receivables turnover for the company is 3.62 and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.31.